Zacks Research Issues Positive Outlook for LLY Earnings

Eli Lilly and Company (NYSE:LLY) – Equities researchers at Zacks Research boosted their Q2 2025 EPS estimates for shares of Eli Lilly and Company in a note issued to investors on Thursday, February 27th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $5.48 per share for the quarter, up from their previous estimate of $5.26. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $23.48 per share. Zacks Research also issued estimates for Eli Lilly and Company’s Q4 2025 earnings at $7.09 EPS, FY2025 earnings at $23.32 EPS, Q4 2026 earnings at $9.40 EPS, FY2026 earnings at $31.12 EPS and FY2027 earnings at $39.04 EPS.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%.

Other equities research analysts also recently issued reports about the stock. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Bank of America reiterated a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Finally, Citigroup lowered their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,000.28.

Eli Lilly and Company Price Performance

LLY opened at $920.44 on Monday. The firm has a market cap of $872.73 billion, a P/E ratio of 78.60, a PEG ratio of 1.40 and a beta of 0.42. The firm has a 50-day moving average of $814.88 and a 200 day moving average of $848.12. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. BridgePort Financial Solutions LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $180,000. Park Square Financial Group LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $1,218,000. Menard Financial Group LLC grew its holdings in shares of Eli Lilly and Company by 6.4% in the fourth quarter. Menard Financial Group LLC now owns 810 shares of the company’s stock valued at $625,000 after purchasing an additional 49 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $406,022,000. Finally, Employees Retirement System of Texas grew its holdings in Eli Lilly and Company by 6.1% during the 4th quarter. Employees Retirement System of Texas now owns 205,168 shares of the company’s stock worth $158,390,000 after acquiring an additional 11,816 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.65%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 51.24%.

Eli Lilly and Company announced that its Board of Directors has authorized a stock repurchase program on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.